NCT00002273已完成不适用
Double-Blind, Placebo-Controlled Study of Intravenous Ganciclovir (DHPG) for Cytomegalovirus Colitis in Patients With Acquired Immune Deficiency Syndrome
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
To attempt to demonstrate the efficacy of ganciclovir (DHPG) treatment of cytomegalovirus (CMV) colitis in AIDS patients by evaluating both clinical and virologic parameters. To determine acceptability and the safety profile of a 2-week course of intravenous (IV) DHPG therapy.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •An underlying diagnosis of AIDS by CDC surveillance definition (group IV, category c-1 or subgroup D only).
- •Colitis manifested clinically by diarrhea.
- •Colon biopsy demonstrating a typical histologic picture of cytomegalovirus (CMV) disease.
- •Cultures for CMV from blood and urine should be obtained within 1 week of study entry but need not be positive prior to entry. (A positive culture is needed for final inclusion in AN.)
- •Prior Medication:
- •Topical acyclovir.
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •History of chronic or acute liver disease.
- •History of significant mental illness.
- •Life expectancy < 1 month.
- •Presence of any cause of colitis other than cytomegalovirus (CMV). (The following tests must be negative:
- •Stool culture for enteric bacterial pathogens, stool exam for ova and parasites, stool exam for cryptosporidia, stool exam for AFB.) Colitis that is so severe that it would be against the patient's best interest to be treated with placebo for 2 weeks prior to being eligible to receive ganciclovir (DHPG) on a "compassionate" use basis. Patients with a colitis of this severity should be treated with DHPG on "compassionate" use basis.
- •Presence of clinically significant extra-colonic active CMV disease of retina or visceral organs (which could progress during the no-treatment period).
- •Presence of significant renal disease resulting in any decrement of creatinine clearance from normal.
- •Concurrent Medication:
- •Any other investigational drug, whether or not as part of a formal clinical study.
- •Patients with the following are excluded:
- •History of chronic or acute liver disease.
- •History of significant mental illness.
- •Life expectancy < 1 month.
- •Presence of any cause of colitis other than cytomegalovirus (CMV). (The following tests must be negative:
- •Stool culture for enteric bacterial pathogens, stool exam for ova and parasites, stool exam for cryptosporidia, stool exam for AFB.) Colitis that is so severe that it would be against the patient's best interest to be treated with placebo for 2 weeks prior to being eligible to receive ganciclovir (DHPG) on a "compassionate" use basis. Patients with a colitis of this severity should be treated with DHPG on "compassionate" use basis.
- •Presence of clinically significant extra-colonic active CMV disease of retina or visceral organs (which could progress during the no-treatment period).
- •Presence of significant renal disease resulting in any decrement of creatinine clearance from normal.
- •Prior Medication:
- •Excluded within 2 days of study entry:
- •Nucleoside analogs.
- •Excluded within 1 week of study entry:
- •Antimetabolites or interferon.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency VirusCytomegalovirus InfectionsHIV InfectionsNCT00002095Hoffmann-La Roche700
已完成
2 期
The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVCytomegalovirus RetinitisGastrointestinal DiseasesHIV InfectionsNCT00001034National Institute of Allergy and Infectious Diseases (NIAID)850
已完成
不适用
A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus RetinitisCytomegalovirus RetinitisHIV InfectionsNCT00002134Roche Global Development450
已完成
3 期
A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDSCytomegalovirus RetinitisHIV InfectionsNCT00000688National Institute of Allergy and Infectious Diseases (NIAID)180
终止
2 期
Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster KeratitisHerpes Zoster KeratitisNCT02382588Northwestern University8